Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 291

1.

In-office Transperineal Prostate Biopsy Using Biplanar Ultrasound Guidance: A Step-by-Step Guide.

Zimmerman ME, Meyer AR, Carter HB, Allaf ME, Gorin MA.

Urology. 2019 Jul 30. pii: S0090-4295(19)30684-3. doi: 10.1016/j.urology.2019.07.021. [Epub ahead of print]

PMID:
31374287
2.

Association between Liver Fibrosis and Serum PSA among U.S. Men: National Health and Nutrition Examination Survey (NHANES), 2001-2010.

Wang A, Lazo M, Carter HB, Groopman JD, Nelson WG, Platz EA.

Cancer Epidemiol Biomarkers Prev. 2019 Aug;28(8):1331-1338. doi: 10.1158/1055-9965.EPI-19-0145. Epub 2019 Jun 3.

PMID:
31160348
3.

Editorial Comment.

Carter HB.

J Urol. 2019 May;201(5):922. doi: 10.1097/01.JU.0000554387.61658.af. No abstract available.

PMID:
30821621
4.

ESTIMATING AND COMPARING CANCER PROGRESSION RISKS UNDER VARYING SURVEILLANCE PROTOCOLS.

Lange JM, Gulati R, Leonardson AS, Lin DW, Newcomb LF, Trock BJ, Carter HB, Cooperberg MR, Cowan JE, Klotz LH, Etzioni R.

Ann Appl Stat. 2018 Sep;12(3):1773-1795. doi: 10.1214/17-AOAS1130. Epub 2018 Sep 11.

5.

Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.

Carter HB, Helfand B, Mamawala M, Wu Y, Landis P, Yu H, Wiley K, Na R, Shi Z, Petkewicz J, Shah S, Fantus RJ, Novakovic K, Brendler CB, Zheng SL, Isaacs WB, Xu J.

Eur Urol. 2019 May;75(5):743-749. doi: 10.1016/j.eururo.2018.09.021. Epub 2018 Oct 8.

6.

PTEN status assessment in the Johns Hopkins active surveillance cohort.

Tosoian JJ, Guedes LB, Morais CL, Mamawala M, Ross AE, De Marzo AM, Trock BJ, Han M, Carter HB, Lotan TL.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):176-181. doi: 10.1038/s41391-018-0093-2. Epub 2018 Oct 2.

7.

Clinical Evaluation of an Individualized Risk Prediction Tool for Men on Active Surveillance for Prostate Cancer.

Huntley JH, Coley RY, Carter HB, Radhakrishnan A, Krakow M, Pollack CE.

Urology. 2018 Nov;121:118-124. doi: 10.1016/j.urology.2018.08.021. Epub 2018 Aug 30.

PMID:
30171924
8.

Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance.

Druskin SC, Mamawala M, Tosoian JJ, Epstein JI, Pavlovich CP, Carter HB, Trock BJ.

J Urol. 2019 Jan;201(1):98-104. doi: 10.1016/j.juro.2018.08.023.

PMID:
30114397
9.

Germline mutations in PPFIBP2 are associated with lethal prostate cancer.

Wu Y, Yu H, Zheng SL, Feng B, Kapron AL, Na R, Boyle JL, Shah S, Shi Z, Ewing CM, Wiley KE, Luo J, Walsh PC, Carter HB, Helfand BT, Cooney KA, Xu J, Isaacs WB.

Prostate. 2018 Dec;78(16):1222-1228. doi: 10.1002/pros.23697. Epub 2018 Jul 24.

PMID:
30043417
10.

Stratifying Risk for Men With Low-Volume Intermediate-Risk Prostate Cancer-Reply.

Patel HD, Tosoian JJ, Carter HB, Epstein JI.

JAMA Oncol. 2018 Aug 1;4(8):1133-1134. doi: 10.1001/jamaoncol.2018.0754. No abstract available.

PMID:
29852039
11.

Prostate-Specific Antigen (PSA) Screening for Prostate Cancer: Revisiting the Evidence.

Carter HB.

JAMA. 2018 May 8;319(18):1866-1868. doi: 10.1001/jama.2018.4914. No abstract available.

PMID:
29800999
12.

Subtyping the Risk of Intermediate Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy.

Patel HD, Gupta M, Tosoian JJ, Carter HB, Partin AW, Epstein JI.

J Urol. 2018 Nov;200(5):1068-1074. doi: 10.1016/j.juro.2018.04.058. Epub 2018 Apr 17.

PMID:
29673946
13.

A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.

Wu Y, Yu H, Zheng SL, Na R, Mamawala M, Landis T, Wiley K, Petkewicz J, Shah S, Shi Z, Novakovic K, McGuire M, Brendler CB, Ding Q, Helfand BT, Carter HB, Cooney KA, Isaacs WB, Xu J.

Prostate. 2018 Jun;78(8):607-615. doi: 10.1002/pros.23505. Epub 2018 Mar 9.

PMID:
29520813
14.

Risk Stratification in Active Surveillance: A Dynamic, Ever-Evolving Practice.

Tosoian JJ, Carter HB.

Eur Urol. 2018 May;73(5):713-714. doi: 10.1016/j.eururo.2018.02.006. Epub 2018 Feb 17. No abstract available.

PMID:
29458984
15.

Targeted antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy during active surveillance: Effect on hospitalization.

Cheung C, Patel HD, Landis P, Carter HB, Han M.

Urol Oncol. 2018 Apr;36(4):158.e7-158.e12. doi: 10.1016/j.urolonc.2017.12.005. Epub 2017 Dec 26.

PMID:
29288004
16.

Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.

Druskin SC, Tosoian JJ, Young A, Collica S, Srivastava A, Ghabili K, Macura KJ, Carter HB, Partin AW, Sokoll LJ, Ross AE, Pavlovich CP.

BJU Int. 2018 Apr;121(4):619-626. doi: 10.1111/bju.14098. Epub 2018 Jan 9.

17.

Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.

Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R.

Ann Intern Med. 2018 Jan 2;168(1):1-9. doi: 10.7326/M17-0548. Epub 2017 Nov 28.

18.

Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.

Tosoian JJ, Mamawala M, Patel HD, Alam R, Epstein JI, Ross AE, Carter HB.

J Urol. 2018 Apr;199(4):954-960. doi: 10.1016/j.juro.2017.10.029. Epub 2017 Oct 24. Erratum in: J Urol. 2018 May 8;:.

PMID:
29074222
19.
20.

Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Con.

Tosoian JJ, Carter HB.

J Urol. 2017 Nov;198(5):997-999. doi: 10.1016/j.juro.2017.08.088. Epub 2017 Sep 22. Review. No abstract available.

PMID:
28947084

Supplemental Content

Loading ...
Support Center